Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas

Jung Soo Lim, Mi Kyung Lee, Eunhee Choi, Namki Hong, Soo Il Jee, Sun Ho Kim, Eunjig Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The molecular mechanisms underlying tumor growth in Cushing’s disease (CD) still remain a challenge. Moreover, clinical manifestations of CD may vary depending on hormonal activity; however, factors involved in the hormonal aggressiveness of adrenocorticotropic hormone (ACTH)-secreting pituitary tumors have not been fully clarified. We investigated the association between the expression of cellular markers regarding pituitary tumor progression and initial or postoperative hormone levels in patients with CD. Methods: Tumor tissues from 28 corticotroph adenomas (female 26, male 2, mean age 39.21 ± 10.39 years) were subject to immunohistochemical study using the following antibodies: pituitary tumor-transforming gene 1 (PTTG1), cyclin D1, p16, p27, brahma related-gene 1 (Brg1), and Ki-67. We then analyzed the relationship between each cellular marker expression and hormone levels, including 24 h urinary free cortisol (UFC), plasma ACTH, and serum cortisol. Results: PTTG1 and Ki-67 were expressed in 100% and 50% of patients, respectively. However, the levels did not reflect initial hormonal activity. The cyclin D1-negative group showed higher serum cortisol levels compared to the cyclin D1-positive group (p = 0.01). The 24 h UFC levels were significantly higher in the p27-negative group than in the p27-positive group (p = 0.04), whereas the Brg1-positive group revealed higher serum cortisol levels than in the Brg1-negative group (p = 0.02). Conclusions: Although PTTG1 and Ki-67 play an essential role in developing ACTH-secreting tumors, cyclin D1, p27, and Brg1 may be better biomarkers to determine hormonal aggressiveness of the tumor. Further research is needed to understand the influence of cellular markers on hormonal activity in CD.

Original languageEnglish
Pages (from-to)147-156
Number of pages10
JournalEndocrine
Volume64
Issue number1
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

ACTH-Secreting Pituitary Adenoma
Pituitary Neoplasms
Pituitary ACTH Hypersecretion
Cyclin D1
Hydrocortisone
Oncogenes
Adrenocorticotropic Hormone
Genes
Neoplasms
Serum
Hormones
Biomarkers
Antibodies
Growth
Research

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Lim, Jung Soo ; Lee, Mi Kyung ; Choi, Eunhee ; Hong, Namki ; Il Jee, Soo ; Kim, Sun Ho ; Lee, Eunjig. / Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas. In: Endocrine. 2019 ; Vol. 64, No. 1. pp. 147-156.
@article{ac75865a0dcd4d778ffb879aebbcb52b,
title = "Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas",
abstract = "Purpose: The molecular mechanisms underlying tumor growth in Cushing’s disease (CD) still remain a challenge. Moreover, clinical manifestations of CD may vary depending on hormonal activity; however, factors involved in the hormonal aggressiveness of adrenocorticotropic hormone (ACTH)-secreting pituitary tumors have not been fully clarified. We investigated the association between the expression of cellular markers regarding pituitary tumor progression and initial or postoperative hormone levels in patients with CD. Methods: Tumor tissues from 28 corticotroph adenomas (female 26, male 2, mean age 39.21 ± 10.39 years) were subject to immunohistochemical study using the following antibodies: pituitary tumor-transforming gene 1 (PTTG1), cyclin D1, p16, p27, brahma related-gene 1 (Brg1), and Ki-67. We then analyzed the relationship between each cellular marker expression and hormone levels, including 24 h urinary free cortisol (UFC), plasma ACTH, and serum cortisol. Results: PTTG1 and Ki-67 were expressed in 100{\%} and 50{\%} of patients, respectively. However, the levels did not reflect initial hormonal activity. The cyclin D1-negative group showed higher serum cortisol levels compared to the cyclin D1-positive group (p = 0.01). The 24 h UFC levels were significantly higher in the p27-negative group than in the p27-positive group (p = 0.04), whereas the Brg1-positive group revealed higher serum cortisol levels than in the Brg1-negative group (p = 0.02). Conclusions: Although PTTG1 and Ki-67 play an essential role in developing ACTH-secreting tumors, cyclin D1, p27, and Brg1 may be better biomarkers to determine hormonal aggressiveness of the tumor. Further research is needed to understand the influence of cellular markers on hormonal activity in CD.",
author = "Lim, {Jung Soo} and Lee, {Mi Kyung} and Eunhee Choi and Namki Hong and {Il Jee}, Soo and Kim, {Sun Ho} and Eunjig Lee",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s12020-018-1815-x",
language = "English",
volume = "64",
pages = "147--156",
journal = "Endocrine",
issn = "0969-711X",
publisher = "Humana Press",
number = "1",

}

Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas. / Lim, Jung Soo; Lee, Mi Kyung; Choi, Eunhee; Hong, Namki; Il Jee, Soo; Kim, Sun Ho; Lee, Eunjig.

In: Endocrine, Vol. 64, No. 1, 01.04.2019, p. 147-156.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas

AU - Lim, Jung Soo

AU - Lee, Mi Kyung

AU - Choi, Eunhee

AU - Hong, Namki

AU - Il Jee, Soo

AU - Kim, Sun Ho

AU - Lee, Eunjig

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose: The molecular mechanisms underlying tumor growth in Cushing’s disease (CD) still remain a challenge. Moreover, clinical manifestations of CD may vary depending on hormonal activity; however, factors involved in the hormonal aggressiveness of adrenocorticotropic hormone (ACTH)-secreting pituitary tumors have not been fully clarified. We investigated the association between the expression of cellular markers regarding pituitary tumor progression and initial or postoperative hormone levels in patients with CD. Methods: Tumor tissues from 28 corticotroph adenomas (female 26, male 2, mean age 39.21 ± 10.39 years) were subject to immunohistochemical study using the following antibodies: pituitary tumor-transforming gene 1 (PTTG1), cyclin D1, p16, p27, brahma related-gene 1 (Brg1), and Ki-67. We then analyzed the relationship between each cellular marker expression and hormone levels, including 24 h urinary free cortisol (UFC), plasma ACTH, and serum cortisol. Results: PTTG1 and Ki-67 were expressed in 100% and 50% of patients, respectively. However, the levels did not reflect initial hormonal activity. The cyclin D1-negative group showed higher serum cortisol levels compared to the cyclin D1-positive group (p = 0.01). The 24 h UFC levels were significantly higher in the p27-negative group than in the p27-positive group (p = 0.04), whereas the Brg1-positive group revealed higher serum cortisol levels than in the Brg1-negative group (p = 0.02). Conclusions: Although PTTG1 and Ki-67 play an essential role in developing ACTH-secreting tumors, cyclin D1, p27, and Brg1 may be better biomarkers to determine hormonal aggressiveness of the tumor. Further research is needed to understand the influence of cellular markers on hormonal activity in CD.

AB - Purpose: The molecular mechanisms underlying tumor growth in Cushing’s disease (CD) still remain a challenge. Moreover, clinical manifestations of CD may vary depending on hormonal activity; however, factors involved in the hormonal aggressiveness of adrenocorticotropic hormone (ACTH)-secreting pituitary tumors have not been fully clarified. We investigated the association between the expression of cellular markers regarding pituitary tumor progression and initial or postoperative hormone levels in patients with CD. Methods: Tumor tissues from 28 corticotroph adenomas (female 26, male 2, mean age 39.21 ± 10.39 years) were subject to immunohistochemical study using the following antibodies: pituitary tumor-transforming gene 1 (PTTG1), cyclin D1, p16, p27, brahma related-gene 1 (Brg1), and Ki-67. We then analyzed the relationship between each cellular marker expression and hormone levels, including 24 h urinary free cortisol (UFC), plasma ACTH, and serum cortisol. Results: PTTG1 and Ki-67 were expressed in 100% and 50% of patients, respectively. However, the levels did not reflect initial hormonal activity. The cyclin D1-negative group showed higher serum cortisol levels compared to the cyclin D1-positive group (p = 0.01). The 24 h UFC levels were significantly higher in the p27-negative group than in the p27-positive group (p = 0.04), whereas the Brg1-positive group revealed higher serum cortisol levels than in the Brg1-negative group (p = 0.02). Conclusions: Although PTTG1 and Ki-67 play an essential role in developing ACTH-secreting tumors, cyclin D1, p27, and Brg1 may be better biomarkers to determine hormonal aggressiveness of the tumor. Further research is needed to understand the influence of cellular markers on hormonal activity in CD.

UR - http://www.scopus.com/inward/record.url?scp=85057141836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057141836&partnerID=8YFLogxK

U2 - 10.1007/s12020-018-1815-x

DO - 10.1007/s12020-018-1815-x

M3 - Article

VL - 64

SP - 147

EP - 156

JO - Endocrine

JF - Endocrine

SN - 0969-711X

IS - 1

ER -